Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 18, 2007

NicOx Achieves First Milestone of Euro 5M From Merck

  • NicOx initiated GLP toxicology studies on the first antihypertensive candidate selected along with Merck & Co., according to a deal between the two firms. NicOx thus received its first milestone of Euro 5 million.

    NicOx and Merck have been working together since March 2006 to develop and commercialize new antihypertensive drugs using NicOx' nitric oxide-donating technology for the treatment of high blood pressure, complications of hypertension, and other cardiovascular and related disorders.

    NicOx previously received Euro 9.2 million from Merck and stands to receive Euro 274 million in future potential milestone payments.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »